Challenges in the use of corticosteroids in the management of autoimmune hepatitis.
Challenges in the use of corticosteroids in the management of autoimmune hepatitis.
Br J Hosp Med (Lond). 2019 Oct 02;80(10):594-599
Authors: Chapman RW, Aspinall RJ, Trivedi P, Wright G, Heneghan M
Abstract
Autoimmune hepatitis is widely assumed by health-care professionals to be a disease that is easily controlled through the use of corticosteroids and immunosuppressants but recent studies in the UK indicate highly variable treatment regimens and often unsatisfactory treatment outcomes, such as dependence on long-term high-dose steroids and ongoing need for liver transplantation in some cases. The therapeutic use of the systemically acting corticosteroid prednisolone results in unacceptable side effects in many patients. Recent evidence suggests that it is not always necessary to use high-dose steroids (>0.5 mg/kg/d) to attain remission; and side effects may also be minimised through more targeted therapy with the less systemically-absorbed corticosteroid, budesonide. The authors offer advice on the stratification of treatment for these patients and suggest changes to improve the services available for people with autoimmune hepatitis in the UK.
PMID: 31589514 [PubMed - in process]
Source: British Journal of Hospital Medicine - Category: Internal Medicine Authors: Chapman RW, Aspinall RJ, Trivedi P, Wright G, Heneghan M Tags: Br J Hosp Med (Lond) Source Type: research
More News: Autoimmune Disease | Corticosteroid Therapy | Health Management | Hepatitis | Hepatitis B | Hospitals | Internal Medicine | Liver | Liver Transplant | Prednisolone | Study | Transplants | UK Health | Urology & Nephrology